The company guarantees regulatory approvals for commercial deployment in the United Kingdom and the United States
With more than 55 million people around the world living with dementia, Oxford Brain Diagnostics (OBD) is ready to revolutionize early diagnosis with its patented cortical disarray measurement technology (CDM®). The software analyzes standard MRI analyzes to provide an objective measure of neurodegeneration, offering a more precise means of assessing brain health.
Following the FDA 510 (K) and the self-certification of the UKCA, the OBD will now deploy its commercial technology in all health sectors in the United Kingdom and the United States. The company aims to advance the diagnostics of neurodegeneration worldwide, helping health care providers to detect and monitor diseases like Alzheimer’s earlier.
OBD was founded in 2019 by Dr. Steven Chance, former associate professor of neuroscience at the University of Oxford, and Professor Mark Jenkinson, professor of neuroimperie. Built over decades of expertise in pathology and cerebral imaging, CDM® obtained the status of designation of devices of percement by the FDA in 2020 to assess adults at risk of Alzheimer’s disease.
In 2023, the company obtained investments of several million pounds from BGF, the United Kingdom and the most active growth capital investor in Ireland, as well as the continuous support of existing investors, including the Oxford Technology & Innovations Fund. This funding allowed the OBD to guarantee regulatory approvals and commercial deployment, launching the basics of global expansion.
Dr. Steven Chance, CEO and co-founder of the OBD, said: “Neurodegenerative diseases represent an increasing public health challenge, which has an impact on millions of patients and their families around the world. The support of BGF and other investors and partners allows us to accelerate the path to the marketing of our software tool and brings hope to the truth about their health. “
Maggy Lau, investor at BGF, said: “OBD’s progress in the past two years has been remarkable. The technology is really differentiated, and its recent regulatory achievements point out how close it is to make a major impact. We are proud to support a company that takes up one of the most difficult and most important challenges in health care today. “
With the arrival of new anti-amyloid drugs from Alzheimer, an early and precise diagnosis is more crucial than ever. OBD technology responds directly to this need, supporting pharmaceutical trials, drug development and expansion in health establishments.
Beyond dementia, the OBD platform is promising in the detection of Parkinson’s disease and multiple sclerosis, expanding its impact in clinical and research fields